Burning Rock BiotechFRA:6BU0 -17.81%59 Piotroski F-Score is 6 as of Jun. 29, 2026, which is 50% above its 10-year median of 4.00. GuruFocus rates FRA:6BU0 with a GF Score™ of 59/100 and a GF Value™ of €5.43 (Fairly Valued). The stock has 2 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Burning Rock Biotech ranks better than 79.52% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Burning Rock Biotech has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Burning Rock Biotech's Piotroski F-Score or its related term are showing as below:
FRA:6BU0'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 6
Current: 6
During the past 9 years, the highest Piotroski F-Score of Burning Rock Biotech was 6. The lowest was 2. And the median was 4.
Burning Rock Biotech (FRA:6BU0) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Burning Rock Biotech Piotroski F-Score Related Terms
Burning Rock Biotech Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6BU0 vs XGN, IDXG, PRPO: Piotroski F-Score Comparison
For the Diagnostics & Research subindustry, Burning Rock Biotech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech Piotroski F-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Burning Rock Biotech's current Net Income (TTM) was -7.23.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Burning Rock Biotech's return on assets of this year was -0.06632985. Burning Rock Biotech's return on assets of last year was -0.24456189.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Burning Rock Biotech's gearing of this year was 0.03678461. Burning Rock Biotech's gearing of last year was 0.02080809.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Burning Rock Biotech's current ratio of this year was 3.05027216. Burning Rock Biotech's current ratio of last year was 3.01654611.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Burning Rock Biotech's number of shares in issue this year was 10.52. Burning Rock Biotech's number of shares in issue last year was 10.762.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Burning Rock Biotech's gross margin of this year was 0.74535512. Burning Rock Biotech's gross margin of last year was 0.71487204.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Burning Rock Biotech's asset turnover of this year was 0.57345889. Burning Rock Biotech's asset turnover of last year was 0.53444864.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
0
+
1
+
1
+
1
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Burning Rock Biotech has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Burning Rock Biotech (FRA:6BU0) has a Piotroski F-Score of 6 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Burning Rock Biotech and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, Burning Rock Biotech's Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Burning Rock Biotech ranks #43 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 20.5%.
Is Burning Rock Biotech's Piotroski F-Score too high?
Burning Rock Biotech's current Piotroski F-Score of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Burning Rock Biotech's value of 6 is 20% above this industry median. Based on the distribution chart, Burning Rock Biotech ranks #43 out of 210 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Burning Rock Biotech has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Piotroski F-Score compare to XGN and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #43 out of 210 companies for Piotroski F-Score. This places Burning Rock Biotech in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Burning Rock Biotech's value of 6 is 20% above this benchmark. Historically, Burning Rock Biotech's own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Burning Rock Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Burning Rock Biotech's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Burning Rock Biotech and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Burning Rock Biotech's current Piotroski F-Score is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Fairly Valued. The stock's GF Value™ is €5.43, compared to a current price of €6.00 — trading 10.5% above its estimated fair value. The current Piotroski F-Score is 6, which is 50% above median its 10-year median of 4.00 and 20% above the Medical Diagnostics & Research industry median of 5.00. Burning Rock Biotech's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current Piotroski F-Score is 6 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of €6.00 is trading 10.5% above its estimated GF Value™ of €5.43.
GuruFocus considers Burning Rock Biotech to be Fairly Valued.
Key valuation signals for FRA:6BU0:
Piotroski F-Score: 6 (50% above median its 10-year median of 4.00)
GF Value™: €5.43 vs. price of €6.00 (10.5% above fair value)
Industry Position: 20% above the Medical Diagnostics & Research median (#43 of 210)
No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
59GF Score
Get the complete analysis for FRA:6BU0
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6BU0 has been successfully added to your 
